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ABSTRACT
Squamous cell carcinoma is the most common malignant tumour of the head and neck. The initial TNM staging, the
evaluation of the tumour response during treatment, and the long-term surveillance are crucial moments in the approach
to head and neck squamous cell carcinoma (HNSCC). Thus, at each of these moments, the choice of the best diagnostic
tool providing the more precise and larger information is crucial. Positron emission tomography with fluorine-18
fludeoxyglucose integrated with CT (18F-FDG-PET/CT) rapidly gained clinical acceptance, and it has become an
important imaging tool in routine clinical oncology. However, controversial data are currently available, for example, on
the role of 18F-FDG-PET/CT imaging during radiotherapy planning, the prognostic value or its real clinical impact on
treatment decisions. In this article, the role of 18F-FDG-PET/CT imaging in HNSCC during pre-treatment staging,
radiotherapy planning, treatment response assessment, prognosis and follow-up is reviewed focusing on current
evidence and controversial issues. A proposal on how to integrate 18F-FDG-PET/CT in daily clinical practice is also
described.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the
most common malignant tumour of the head and neck
(HN).1 Radiotherapy has a well-established role both in the
exclusive and in the adjuvant setting.2,3 Initial diagnosis
and staging of HNSCC is based on physical examination,
chest imaging, HN endoscopy, and HN CT or MRI. Clin-
ical guidelines for HNSCC recommend different imaging
approaches for each phase of disease.2–4 Moreover, modern
imaging modalities have an essential role in the tumour
response after treatment and follow-up.5–7 Each of the
currently available imaging techniques present different
levels of sensibility and speciﬁcity, and it is essential for the
radiation oncologist to choose the better one, depending
on the clinical scenario.
Positron emission tomography with ﬂuorine-18 ﬂudeox-
yglucose integrated with CT (18F-FDG-PET/CT) rapidly
gained clinical acceptance and has become an important
tool in routine clinical HN oncology. According to the
National Comprehensive Cancer Network guidelines, PET
or PET/CT is suggested (individualized cases) for Stage III
(T3, N0, M0 or T1–3N1M0) and Stage IV (T1–T4, N0–N3,
M0–M1) due to the possibility of stage migration.2 The
Ontario guidelines suggest that 18F-FDG-PET/CT is also
indicated when the primary site is unknown or in the
staging of locally advanced disease.4
It is noteworthy that not all HN guidelines agree8 upon the
usefulness of PET in different potential HN clinical
scenarios.
The aim of this review is to explore the most important available
literature dealing with the role of 18F-FDG-PET/CT imaging in
HNSCC in pre-treatment staging, radiotherapy planning,
treatment response assessment, prognosis and follow-up. Evi-
dences and controversies have been summarized, with particular
attention to the point of view of the radiation oncologist.
METHODS AND MATERIALS
We performed a comprehensive literature search of the MED-
LINE database without any limits to identify relevant studies
(published up to the 31 October 2015) dealing with the topic of
this review. We used the keywords “HNSCC” or “head and neck
cancer” AND “PET-CT” or “PET” with different combinations:
(a) staging, (b) clinical impact, (c) radiotherapy planning, (d)
treatment response and (e) prognosis. The titles and abstracts
were examined for potentially eligible studies for full-text re-
trieval. Results have been presented in Tables 1–5. In addition,
most signiﬁcant articles are detailed in the text. Additional sources
were identiﬁed from references cited in the articles identiﬁed by
electronic searching. Meta-analyses have been also used as source
of articles and brieﬂy described in the text when necessary.
The inclusion criteria were: articles comparing diagnostic
performance (for staging and treatment response) between
PET/PET-CT and conventional imaging (CT, MRI and ultra-
sonography); articles evaluating the role of PET vs conven-
tional imaging for radiotherapy planning; and articles that
evaluated pre-treatment PET/CT metabolic parameters to
predict the outcome of patients with HNSCC undergoing
radical treatment.
The exclusion criteria were: articles regarding the role of PET
limited to nasopharynx carcinoma, thyroid or salivary gland
tumours (considered as speciﬁc clinical entities); studies in-
cluding ,10 patients; and non-English written articles.
Thereafter, the articles have been classiﬁed depending on their
main topic in order to be considered in each of the sections of
this article (pre-therapeutic staging, impact on treatment deci-
sions, monitoring treatment response, radiotherapy planning
and prognosis value).
PRE-THERAPEUTIC STAGING
Local tumour extension (T stage)
The correct assessment of the size and extent of a primary lesion
at staging is crucial to plan surgery and radiotherapy. Indeed,
inﬁltration of adjacent structures is an important issue in clinical
routine. For example, the transgression of the midline on the
tongue complicates surgery9 or can modify the clinical target
volume in radiotherapy treatment planning (RTP). The initial
assessment of the local tumour extension is generally performed
with clinical examination and endoscopy.
Even though 18F-FDG-PET/CT detects primary HNSCC with
high sensitivity (.95%),10,11 contrast-enhanced (CE) CT and
MRI have been considered the primary imaging modalities for
evaluating T stage of HNSCC due to their superior anatomical
resolution and tissue contrast.
Since it is not possible to exactly deﬁne the size and extent of
a primary lesion based on 18F-FDG uptake, the PET (alone)
images are not suitable to deﬁne the T stage of a patient. In
addition, the main limitation of hybrid PET/CT, if performed
with low-dose unenhanced CT, is its inability to accurately assess
the extent of tumour spread and its relationship with adjacent
structures.
Table 1. Diagnostic performance of positron emission tomography (PET)/CT for unknown primary carcinoma
Study Year
Number of
patients
Study
design
Primary tumour detection
rate (%)
Sensitivity
(%)
Specificity
(%)
Regelink et al18 2002 50 Retrospective 32 100 94
Stockeli et al19 2003 18 Prospective 33 63 90
Gutzeit et al20 2005 18 Retrospective 33 35 0 (0/1)
Freudenberg
et al25
2005 21 Retrospective 57 86 100
Fakrhy et al21 2006 22 Retrospective 32 70 75
Nassenstein
et al22
2007 39 NR 28 100 85
Wartski et al23 2007 38 Retrospective 34 93 73
Johansen et al26 2008 60 Prospective 37 87 68
Rogh et al27 2009 44 Retrospective 43 87.5 82.1
Zhao et al28 2012 25 Retrospective 84 73.3 28.6
Wong et al24 2012 78 Retrospective 38.5 100 66.7
Pereira et al29 2012 49 Retrospective 18.4 69.2 81.6
Lee et al30 2015 56 Prospective 50 69 88
NR, not reported.
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Moreover, although PET/CT performed with contrast-enhanced
CT provides both anatomical and metabolic details at the same
time, there is no clear recommendation for routine use of PET/
CT in initial T staging.
Some authors showed the high potential value of PET/CT to
identify the local tumour extension.11,12 Interestingly, Baek
et al11 retrospectively reviewed 69 patients with oral cavity
cancer (OCC) who had non-removable dental metallic implants
at the time of the pre-treatment imaging work-up and on whom
CT or MRI plus PET/CT was performed for the initial staging.
The aim was to analyze the clinical impact of PET/CT for pri-
mary tumour detection and volume estimation in patients
presenting this particular clinical situation. A total of 64 PET/
CT, 64 CT and 27 MRI were analyzed. PET/CT was more ac-
curate in detecting primary tumours than CT in patients with
OCC and dental artefacts (95.3% vs 75.0%, respectively;
p5 0.0016). Among the 27 subjects who had undergone all the
three diagnostic modalities, the diagnostic performance for the
detection of primary tumours in the oral cavity was 96.3%,
77.8% and 85.2%, respectively (not statistically signiﬁcant).
Rodrigues et al12 retrospectively evaluated 44 patients who un-
derwent primary tumour resection and neck dissection. They
compared the performance of CE-CT, a dedicated HN PET/CT
(the latter being a CE-CT) and an optimized whole-body (WB)
PET/CT scan. The primary tumour was correctly identiﬁed by
CE-CT, WB PET/CT and HN PET/CE-CT in 71%, 92% and
95% of cases, respectively. Both (WB and HN) PET protocols
demonstrated signiﬁcantly better performance than did CE-CT
in identifying the primary site of the tumour. However, there
was no statistical difference in the detection of the primary le-
sion between WB PET/CT and HN PET/CE-CT protocols.12 A
major limit of this study is the lack of comparison with the MRI
performance. Moreover, 66% of the patients participating in the
study presented an oropharyngeal carcinoma, making difﬁcult
to infer these data in HN neoplasms of different origin.
Mandibular invasion
The presence or absence of mandibular invasion is a major
determinant in both therapeutic approach and prognosis of
HNSCC.13 CT and MRI are commonly used to evaluate the
status of the mandible. CT has been reported to be the most
accurate method in evaluating discrete cortical bone in-
volvement.14 However, MRI is superior to CT for evaluating
tumour invasion into medullary cavity of the mandible.15
Gu et al16 performed a direct comparison of CT and MRI and
PET/CT in the detection of mandibular invasion by OCC. The
sensitivity was 47.1%, 58.3% and 58.3% for CT, MRI and PET/
CT, respectively. The speciﬁcity was 100%, 97.1% and 97.1% for
CT, MRI and PET/CT, respectively. No statistically signiﬁcant
differences in sensitivity and speciﬁcity were detected between
the three imaging modalities. A recent retrospective study
compared the diagnostic performance from PET/CT and MRI
for the detection of bone marrow invasion of the mandible in
patients with OCC (surgical specimen was used as the standard).
PET/CT was found to be more speciﬁc than MRI (83% vs 61%,
respectively, p 5 0.0015) but less sensitive (78% vs 97%, re-
spectively, p 5 0.0391). Given the low positive-predictive value
(PPV) of MRI, a positive MRI scan should incite to conﬁrm data
Table 2. Studies comparing positron emission tomography (PET) vs CT, MRI and ultrasonography with histopathology of cervical
lymph nodes
Author Year Type of study n
CT/MRI/
ultrasonographya
Sensitivity (%) Specificity (%)
PET/
PET-CT
CT/MRI/
ultrasonography
PET/
PET-CT
CT/MRI/
ultrasonography
Adams
et al36
1998 Prospective 60
CT
MRI
Ultrasonography
90
82
80
79
94
85
79
–
Hannah
et al37
2002 Prospective 40 CT 82 81 94 81
Ng et al38 2006 Prospective 134
CT
MRI
41.2
20
22.2
96.8
97.3
97.4
Kim et al41 2007 Prospective 32 CT/MRIb 96.5 75.9 90 90
Yoon
et al42
2009 Retrospective 67
CT
MRI
Ultrasonography
81.1
77
77
78.4
98.2
99.4
99.4
98.5
Kyzas
et al43
2008
Meta-analysis (32
studies)
1236
–
c
CT vs PET
MRI vs PET
Ultrasonography vs PET
79 (all)
82
78
45
–
74
78
42
86 (all)
86
85
88
76
80
96
aType of imaging compared to PET.
bAll patients underwent CT and/or MRI (reported together).
cAlso compared the performance of fluorine-18 fludeoxyglucose PET with that of conventional diagnostic methods (i.e. CT, MRI and ultrasonography
with fine-needle aspiration).
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with PET, which shows higher PPV, whereas a negative MRI scan
can conﬁdently exclude the presence of bone marrow invasion.15
Cancer from unknown primary
The incidence of cervical metastases from unknown primary
cancer (UPC) has been estimated to be around 2–9%. The
absence of information about the primary tumour strongly
inﬂuences the therapeutic approach (i.e. bilateral tonsillecto-
mies, additional pharyngeal mucosa ﬁeld irradiation).17 PET/
CT can identify approximately 30%18–24 of tumours in patients
presenting cervical lymph node metastases from UPC, in
whom the primary was not detected by the comprehensive
diagnostic work-up including endoscopy and conventional
imaging methods (CT or MRI). Table 1 summarizes the di-
agnostic performance of PET/CT in these studies.18–30 It is
noteworthy that it should be performed before examination
under anaesthesia for targeted panendoscopy and biopsy,
avoiding potential false positives due to the inﬂammation that
usually follows these kinds of procedures.26 Thus, a rigorous
physical examination is still essential, considering that small
and superﬁcial tumours may not have enough 18F-FDG avidity
to be detected by PET/CT, as showed by Thiagarajan5 and
Daisne et al.31
Recently, Zhu et al32 performed a meta-analysis analyzing a total
of 7 studies (246 patients). The primary tumour detection rate,
sensitivity and speciﬁcity of PET/CTwere 44% [95% conﬁdence
interval (CI)5 0.31–0.58], 97% (95% CI5 0.63–0.99) and 68%
(95% CI 5 0.49–0.83).
The largest prospective study evaluating the diagnostic perfor-
mance of PET/CT in UPC has been published by Johansen
et al.26 The authors report data about 60 patients presenting
a primary tumour detection rate of 30%, and the sensitivity and
speciﬁcity rates were 86% and 69%, respectively. However, this
study had several limits, namely, it used three different PET
engines, and among them one was PET/CT, whereas in two
cases, it was PET alone.
Table 3. Results of positron emission tomography (PET) or PET/CT and other imaging tools in M staging of head and neck
(HN) cancer
Author Year
Type
of study
n Imaging tool
DM
%a
Results
Sensitivity PET
or PET/
CT (%)
Specificity PET
or PET/
CT (%)
Sensitivity CT/
MRI/bone
scintigraphy (%)
Specificity CT/
MRI/bone
scintigraphy (%)
de Bree
et al52,b
2000 Retrospective 101
HN CT/MRI
Chest CT
Bone
scintigraphy
Liver ultrasound
or abdominal CT
17 – – – –
Brower
et al53
2005 Retrospective 109 Chest CT 18c – – 73 80
Ng et al60 2008 Prospective 160
Extended CT
vs PETd
16.3 76.9 94 50 97.8
Senft
et al61
2008 Prospective 145 Chest CT vs PET 28 53 93 37 95
Kim
et al62
2007 Prospective 349
HN CT/MRI 1
PET/CTe
7.4 97.5 96.2 – –
Haerle
et al63
2011 Retrospective 299 PET/CTf 10 96.8 95.4 – –
Xu et al58 2011 Meta-analysis 1445
PET
PET/CT
14.4
84.8
87.5
95.2
95
–
–
–
–
Yi et al59 2013 Meta-analysisg 2764
PET
PET/CT
PET or PET/CT
vs Bone
scintigraphy
–
81
89
85
–
99
99
98
–
–
–
–
55
–
–
–
98
DM, distant metastasis.
aDMs detected by PET.
bScreening for DM without PET.
cThis percentage represents metastasis detected by chest CT. There are no comparisons with other imaging.
dFrom the skull base to the lower abdomen.
eAll patients underwent contrast-enhanced CT or MRI of the HN. Whole-body fluorine-18 fludeoxyglucose PET/CT was also performed in all patients to
identify second primary or distant metastatic cancers. There was no comparison between PET/CT and other imaging modalities.
fNo comparison was performed between PET/CT and other imaging modalities.
gMeta-analysis to evaluate fluorine-18 fludeoxyglucose PET/PET-CT for the detection of bone metastases.
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Furthermore, in some cases, PET was acquired for WB, in other
cases for half body. Furthermore, the authors did not perform
extensive comparison with other imaging modalities.
In summary, physical examination remains essential5 for
primary tumour assessment (especially regarding superﬁcial
tumour extension in the mucosa) while CE-CT and MRI
continue to be the reference imaging modalities, mostly due
to the lack of shown superiority of PET over morphological
examination; however, PET seems to be a promising staging
tool, in particular, when morphological examinations suffer
from artefacts due to dental implants. Finally, when com-
pared with conventional imaging, PET/CT is recommended
to identify primary tumours in patients presenting with
cervical lymph node metastases with unknown primary.
Nevertheless, it needs opportune integration with other di-
agnostic procedure to exclude the relatively high risk of false-
positive ﬁndings.
Lymph node involvement (nodal staging)
The information about nodal involvement is crucial in HNSCC,
as it strongly inﬂuences the treatment and prognosis of the
patients.2,3 Current non-invasive staging techniques include
clinical examination, ultrasonography, CE-CT and MRI. The
criteria adopted in the evaluation of the nodal status are the size,
CE and radiological aspect of the nodes (presence of necrosis,
analysis of the capsule to identify any sign of extracapsular ex-
tension).33 These techniques could deﬁne positive nodes with
high speciﬁcity, but present limitations in the evaluation of small
lymph nodes.34–38 The overall diagnostic accuracy (using pa-
thology as the reference standard) of CT and MRI for detecting
metastases in the clinical node negative neck (cN0) is relatively
low. Sensitivities range from 14% to 80% for CT and from 29%
to 85% for MRI, and speciﬁcities range from 80% to 100% for
both CT and MRI.33,35–37
The sensitivity and speciﬁcity of the imaging techniques in-
ﬂuence the clinical practice of the radiation oncologist; patients
presenting an expected risk of nodal involvement exceeding
20%39 undergo a prophylactic treatment of the neck, including
a neck dissection or unilateral and/or bilateral neck
irradiation.39,40 Considering these rates of microscopic in-
volvement, it means that there are at least two thirds of the
patients who are treated on the nodal areas without presenting
a nodal involvement, only because it is not possible to predict
with a better accuracy the “real nodal status of the patients”.
Table 2 summarizes studies comparing the performances of
different imaging approaches in the study of the nodal status of
HNSCC. These studies36–38,41–43 indicate that PET 6 CT is
similar or slightly superior to conventional imaging for the di-
agnosis of neck metastasis.
Kyzas et al43 performed a meta-analysis on this topic in 2008.
Across 32 studies (1236 patients), PET sensitivity was 79% (95%
CI 5 72–85%) and speciﬁcity was 86% (95% CI 5 83–89%).
However, for patients with cN0, sensitivity of PET was only
50% (95% CI 5 37–63%), whereas speciﬁcity was 87% (95%
CI 5 76–93%).
Ng et al38 evaluated prospectively 134 patients with oral HNSCC
with palpably negative neck with 18F-FDG-PET, CT/MRI and
Table 4. Clinical impact of positron emission tomography (PET) or PET/CT
Study Year n
PET alone or PET/
CT % (number of
patients)
Change in
TNM stagesa
Stageb
Moderate
impactc
High
impactc
PET-CT
accuracy
Conventional
work-up accuracy
p-value
Connell
et al56
2007 76
PET: –
PET/CT: 46% (35)
34% (12/35) I–IV 29% 11% –d – –
Scott
et al54
2008 71
PET: 56.3% (40)
PET/CT: 43.7% (31)
31% (22) I–IV 15.5% 18.3% – – –
Lonneux
et al55,e
2010 233
PET: 83% (194)
PET/CT: 17% (39)
43% (100/233) I–IV 5.2% 8.6% 78%f 22%f p, 0.0001
Cacicedo
et al57,e
2015 84 PET/CT: 100% (84) 38% (32/84) III–IV 9.5%h 16.7%h
92.5%g
71.4%f
73.7%g
25%f
p, 0.001
p5 0.021
n, number of patients.
aDiscrepant TNM stages obtained between conventional work-up and the inclusion of PET or PET/CT.
bHead and neck squamous cell carcinoma stages included in the study.
cMedium and high impact: the impact on patient management in these studies was classified as follows: low impact (treatment modality and delivery
unchanged); medium impact (change in the treatment within the same therapeutic modality: changes in the type of surgery on primary cancer and/or
neck dissection, and changes in the dose or radiotherapy fields); or high impact (change in treatment intent and/or treatment modality: curative to
palliation, surgery to chemoradiation or vice versa).
dNot available.
eIn these two studies, treatment decisions were made by a tumour board (pre-PET staging and treatment management plan, and post-PET staging
and treatment plan). Therefore, the pre-PET treatment decision and post-PET treatment decision were both made by the tumour board.
fThis accuracy was calculated for the cases presenting discordant TNMs (n 5 100) between conventional work-up and from adding a PET (not for the
whole population of the study).
gThe overall accuracy regarding the whole population of the study.
hMeaning that the clinical original clinical decision (pre-PET) adopted by the tumour board was changed in approximately one out of five (9.5% 1
16.7% 5 26.2%) patients participating in the study, due to the PET/CT.
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Table 5. Studies evaluating prognostic value of pre-treatment positron emission tomography volumetric parameters
Author n Year Study design Tumour location Treatment Summary results
La et al110 85 2009 Retrospective
Oropharynx
Hypopharynx
Larynx
Oral cavity
CUP
CCRT
An increase in MTV of
17.4m was associated
with an increased hazard
of ﬁrst event (recurrence
or death) (1.9-fold,
p, 0.001), and of death
(2.1-fold, p, 0.001).
SUVmax was not
associated with DFS
or OS
Chung
et al114
82 2009 Retrospective
Nasopharynx
Oropharynx
Hypopharynx
Cisplatin-based CCRT
MTV .40ml indicated
a signiﬁcantly worse DFS
than MTV #40ml (HR,
3.42; 95% CI,
1.04–11.26; p 5 0.04).
SUV did not show any
prognostic impact
on DFS
Kim et al115 69 2011 Retrospective
Oropharynx
Hypopharynx
Larynx
Oral cavity
Surgery 1 RT (6CC)
Patients with MTV
.41ml showed short
DFS and 2.4-fold higher
recurrence or death than
patients with MTV #41
(p 5 0.041)
Park et al116 81 2013 Retrospective
Hypopharynx
Larynx
Surgery 1 RT(6CC)/
cisplatin-based CCRTa
MTV was an
independent prognostic
factor for both LRC (p5
0.018; HR 5 3.141, 95%
CI 5 1.175–8.399) and
OS (p 5 0.008; HR 5
3.758, 95% CI 5
1.415–9.982)
Kao et al117 64 2012 Retrospective
Oropharynx
Hypopharynx
CCRT
Patients with
MTV2.5. 13.6ml had
a signiﬁcantly inferior
2-year PRFS compared
with patients who had
lower MTV2.5 tumours
(39 vs 72%, respectively,
p 5 0.001)
Dibble
et al118
45 2012 Retrospective
Oropharynx
Oral cavity
Surgery 1 RT/CCRT
Primary tumour MTV
(median cut-off point of
7.7ml) was predictive of
OS (p 5 0.04). Primary
tumour TGA (median
cut-off point of 55 g) was
predictive of OS (log
rank p 5 0.08)
Lim et al119 176 2012 Retrospective Oropharynx CCRT/surgery
SUVmax was not associated
with OS after adjusting for
T stage (p 5 0.158). In
multivariate analysis, TLG
and MTV remained
associated with OS after
correcting for T stage
(p 5 0.0125 and 0.0324,
respectively) and HRs of
1.45 and 1.43, respectively
(Continued)
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Table 5. (Continued)
Author n Year Study design Tumour location Treatment Summary results
Lee et al120 57 2012 Retrospective Oropharynx
Surgery/surgery 1
adjuvant therapy
On a univariate analysis,
SUVmax, SUVavg, MTV
and TLG of primary
tumour were signiﬁcant
predictors of
survival. However,
on multivariate
analysis, only patients
with high MTV
($7.78 cm3) showed
signiﬁcantly worse
prognoses (p 5 0.037)
Tang
et al121
83 2012 Retrospective
Oropharynx
Nasopharynx
Hypopharynx
Larynx
Oral cavity
CUP
RT/CCRT
An increase in total
MTV of 17 cm3 was
associated with a 2.1-fold
increase in the risk of
disease progression (p 5
0.0002) and a 2.0-fold
increase in the risk of
death (p 5 0.0048).
SUVmax was not
associated with either
outcome
Moon
et al122
83 2013 Retrospective Tonsil
RT alone
Surgery alone
CCRT
Surgery CCRT or RT
On multivariate analyses,
only TLG (HR 5 1.020,
95% CI 5 1.003–1.037,
p 5 0.023) was an
independent predictive
factor associated with
decreased OS. MTV and
SUVmax were not
associated with
outcomes
Abd
El-Hafez
et al123
126 2013 Prospective Oropharynx Surgery/CCRT
TLG and SUVmax were
independent prognostic
factors for 2-year DSS.
Patients with high (T)TLG
($71.4) had a 2-year DFS
of 52%, whereas 74% for
those with a low (T)TLG
(p 5 0.007); the
2-year-DSS rates were
53% vs 84%, respectively
(p,0.001). Patients with
high (N)SUVmax ($7.5)
had a 2-year DFS of
42% vs 70% for patients
with a low (N)SUVmax
(p 5 0.001); the
2-year-DSS rates were
39% vs 78%,
respectively (p,0.001)
Garsa
et al124
86 2013 Retrospective Oropharynx CCRT
On multivariate analysis,
a total MTV .20.5ml
was associated with
a 13.0-fold increased risk
of death (95% CI 5
1.62–100; p 5 0.016) for
the p16-positive
subgroup compared with
(Continued)
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Table 5. (Continued)
Author n Year Study design Tumour location Treatment Summary results
a 4.27-fold increased risk
of death (95% CI 5
1.28–14.3; p5 0.018) for
the p16-negative
subgroup. SUVmax,
SUVmean failed to predict
DFS or OS
Romesser
et al125
100 2014 Retrospective Oropharynx CCRT
On multivariate analysis,
a larger MTV
(,9.7 cm3) retained
a signiﬁcant correlation
with an increased risk for
distant metastasis (HR5
2.47; 95% CI 5
1.46–4.17; p 5 0.001),
disease progression or
death (HR 5 2.17; 95%
CI 5 1.40–3.38; p 5
0.001), and death (HR 5
2.37; 95% CI 5
1.44–3.89; p 5 0.001).
SUVmax failed to
correlate with any
outcome
Hanamoto
et al126
118 2014 Retrospective
Nasopharynx
Oropharynx
Laryngohypopharyngeal
CCRT
After multivariate
analysis, high MTV
(.25.0ml) and high
TLG (.144.8 g)
remained as
independent, signiﬁcant
predictors of incomplete
response compared with
low MTV (OR 5 13.4;
95% CI 5 2.5–72.9; p 5
0.003) and low TLG (OR
5 12.8; 95% CI 5
2.4–67.9; p 5 0.003),
respectively
Alluri
et al127
70 2014 Retrospective
Oropharynx (HPV
positive)
RT alone/CCRT
CCRT 1 surgery
Surgery 1 CCRT
Total MTV and primary
tumour MTV remained
as independent
prognostic markers for
EFS. There was no
statistically signiﬁcant
association of EFS with
SUVmax, SUVmean and
primary tumour or
overall TLG
Picchio
et al112
19 2014 Retrospective
Oropharynx
Nasopharynx
Larynx
RT/CCRT
MTV ($32.4 cm3) and
TLG ($469.8 g)
predicted patients’
outcome with respect to
all the considered local
and distant disease
control end points
(LRFS, DMFS and DFS).
SUVmean cut-off value
predictive of LRFS and
DFS were 10.8
(Continued)
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their visual correlation. They reported that 18F-FDG-PET was
twice more sensitive than CT/MRI for detecting cervical nodal
metastasis in patients with palpably negative neck (41.2% vs
21.6%, respectively; p 5 0.021). Histopathological analysis was
used as the gold standard to validate the results obtained with
different imaging techniques. The authors concluded that 18F-
FDG-PET presented a false negativity rate (of occult neck me-
tastasis) of ,15% in T1–3 tumours. However, 18F-FDG-PET,
even visually correlated with CT/MRI, was unable to reduce the
rate of false negative to ,20% in patients with T4 tumour (neck
treatment being mandatory regardless of PET results).
Kim et al41 evaluated 32 consecutive patients with oropharyngeal
HNSCC undergoing 18F-FDG-PET and CT/MRI before surgery
(all patients underwent curative resection of their primary
tumours with also node dissection, with 7 having bilateral dis-
sections, for a total of 39 neck sides). Each method was inter-
preted separately to assess primary tumour and cervical node
status. Histopathology specimen (in 29 of 39 dissected neck
sides and in 47 of 163 dissected cervical levels) showed that
18F-FDG-PET was more accurate than CT/MRI, both in
detecting positive neck sides (22/29 vs 28/29, p, 0.05) and on
a level-by-level basis (37/47 vs 45/47, p, 0.05). Interestingly,
18F-FDG-PET identiﬁed metastatic lesions in approximately two
thirds of the morphologically uninvolved nodes.
Cetin et al44 studied 36 patients with HN cancers, clinically and
radiographically N0, by means of PET/CT and compared data
with neck dissection results. The best threshold of the maximum
standardized uptake value (SUVmax) value yielded 84.2% sen-
sitivity and 76.5% speciﬁcity for nodal-level staging.
Roh et al45 assessed prospectively 91 patients with HNSCC and
negative neck palpation. PET/CT was more sensitive on a per-
level basis than CT/MRI (69% vs 39%, p, 0.001), as well as on
a per-patient basis 71% and 50%, respectively (p 5 0.011).
Although PET/CT examination protocols without the use of
contrast medium have been utilized, increasing evidence sup-
ports the use of CE-CT as a part of routine PET/CT
protocols.46,47 Recently, there have been several reports of the
possible superiority of PET/CE-CT over standard PET/CT in
different clinical settings, including better local48 and nodal
analysis.49 Other studies,50,51 conﬁrmed the high accuracy of
nodal staging by PET/CT, in particular, if CE-CT is used during
PET protocol.
In summary, 18F-FDG-PET has high diagnostic performance in
the overall nodal staging of patients with HNSCC. When com-
pared with conventional imaging, PET/CT is similar or superior
for detecting cervical nodal metastases (Table 2). However, this
modality is not yet accurate enough to replace the accuracy of
neck dissection in the identiﬁcation of occult cervical metastasis
in patients with cN0.36–38,41–43
Detection of distant metastasis
The presence of distant metastases is the most important predictor
of patient survival in several cancers. Overall incidence of distant
metastasis in HNSCC is relatively low (2–18%).52 Distant metas-
tases frequently occur in the lungs and are routinely detected by
chest CT (73% sensitivity and 80% speciﬁcity).53 It is noteworthy
that early detection of metastasis has a major impact on patient
management avoiding unnecessary radical treatments.54–57
Xu et al58 conducted a meta-analysis evaluating the accuracy of
PET and PET-CT in the initial M staging of HNSCC. This meta-
analysis suggested that 209 (14.4%) of 1445 patients had distant
metastasis or a second primary tumour (SPT). PET-CT pre-
sented an overall sensibility of 87.5% (95% CI, 78.7–93.6) and
an overall speciﬁcity of 95% (95% CI, 93.1–96.4).
Regarding the detection of bone metastases, Yi et al59 showed in
a recent meta-analysis on .3000 patients, a sensitivity and
Table 5. (Continued)
Author n Year Study design Tumour location Treatment Summary results
Schwartz
et al128
74 2015
Population subanalysis of
Phase III trial
(RTOG 0522)
Oropharynx
Larynx
Hypopharynx
CCRT (cisplatin and
cetuximab)
Primary tumour MTV
was a strong
independent prognostic
factor for PFS. SUVmax
was not associated with
poor treatment
outcomes
Yabuki
et al129
118 2015 Retrospective Larynx RT or CCRT
On multivariate analysis,
the 3-year DFS for
patients with a high
MTV were signiﬁcantly
poorer than those with
a low MTV (p, 0.001)
CC, concurrent chemotherapy; CCRT, concurrent chemoradiotherapy; CI, confidence interval; CUP, carcinoma with unknown primary; DFS,
disease-free survival; DMFS, distant metastasis-free survival; DSS, disease-specific survival; EFS, event free survival (either recurrence of disease at the
primary site, at regional nodes, or at distant metastatic sites or overall patient mortality); HPV, human papillomavirus; HR, hazard ratio; LRC,
locoregional control; LRFS, local recurrence-free survival; MTV, metabolic tumour volume; MTV2.5, PET segmentation used applying on isocontour at
a SUV of 2.5; n, number of patients; (N)SUVmax, nodal SUVmax; OR, odds ratio; OS, overall survival; PFS: progression-free survival; PRFS, primary
relapse-free survival; RT, radiotherapy; RTOG, Radiation Therapy Oncology Group; SUV, standardized uptake value; SUVavg, average SUV; SUVmax,
maximal SUV; SUVmean, mean SUV; TGA, total glycolytic activity; TLG, total lesion glycolysis; (T)TLG, tumour total lesion glycolysis.
aSeveral patients received induction chemotherapy.
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a speciﬁcity of 81% and 99% for PET, and of 89% and 99% for
PET/CT, respectively, which are better than the results obtained
by bone scintigraphy. Bone scintigraphy relies on the osteo-
blastic response to bone destruction by cancer cells and the
accompanying increase in blood ﬂow. Therefore, 18F-FDG-PET
is more efﬁcient than bone scintigraphy for bone lesion de-
tection considering their frequently lytic character.59
Table 3 summarizes available studies comparing the perform-
ances of different imaging approaches to detect distant metas-
tasis of HNSCC.52,53,58–63 Globally, all these studies indicate that
PET6CT is superior to conventional imaging.
18F-FDG-PET shows higher accuracy (90–95%) than CT for the
detection of distant metastasis.60,61,63 Given the very high
negative-predictive value (NPV), it suggests that in case of
negative PET scan, other imaging techniques are not necessary.
Nevertheless, the PPV for detecting SPT or distant metastasis is
around 60%, suggesting that additional diagnostic methods are
still necessary to exclude false-positive results.62
Senft et al61 assessed the added value of 18F-FDG-PET (to chest
CT) in the screening of distant metastases in patients with
HNSCC and high-risk factors (more than or equal to three
lymph node metastases, bilateral lymph node metastases, lymph
node metastases of $6 cm, low jugular lymph node metastases,
regional tumour recurrence and SPT). 145 consecutive patients
with HNSCC underwent chest CT and 18F-FDG-PET. 18F-FDG-
PET improved pre-treatment screening of distant metastasis
compared with chest CT, showing higher sensitivity (53% vs
37%) and PPV (80% vs 75%). Moreover, the authors showed
that the sensitivity of the combination of CT and 18F-FDG-PET
was higher (63%) than the sensitivity of each of these techni-
ques alone.
Ng et al60 prospectively compared 18F-FDG-PET and extended-
ﬁeld CE-CT (from the skull base to the lower abdomen). A total
of 160 patients with HNSCC of the oropharynx or hypopharynx
underwent 18F-FDG-PET and extended-ﬁeld CT to detect dis-
tant metastases or SPT. In the entire study cohort, a total of
26 patients (16.3%) were found to have distant malignant
lesions. Diagnostic yields of 18F-FDG-PET and extended-ﬁeld
CE-CT were 12.5% (20 out of 160 patients) and 8.1% (13 of
160 patients), respectively. The patient-based sensitivity of
18F-FDG-PET for detection of distant malignancies was 1.5-
times higher than that of extended-ﬁeld CE-CT (76.9% vs
50.0%, p 5 0.039), whereas the patient-based speciﬁcity of
18F-FDG-PET was not signiﬁcantly lower than that of extended-
ﬁeld CE-CT (94.0% vs 97.8%, p 5 0.125).
In summary, when compared with conventional imaging,
PET/CT is a valuable tool to rule out the presence of distant
metastases in HNSCC, especially in locally advanced
tumours.52,53,60–62,64
Second primaries
SPTs are detected in almost 10% of patients with HNSCC,64,65
particularly in patients who smoke and/or in patients who are
negative for human papillomavirus.66
The identiﬁcation of synchronic or metacronic SPT67 could
occur both at the HN region (more frequently) and/or elsewhere
(lungs, oesophagus, colon etc.), and it can inﬂuence the thera-
peutic approach61 and the prognosis of patients (especially those
presenting with HNSCC).68
Strobel et al64 evaluated the role of PET/CT for the initial
staging of HNSCC in 589 consecutive patients for the detection
of synchronous primaries. They detected 56 secondary cancers
in 44 patients. 46 (82%) were found in the aerodigestive tract
as follows: lung (26%), HN (15%) and oesophagus (6%). Nine
synchronous cancers were detected by endoscopy and lost at
PET/CT. The prevalence of synchronous primaries according
to the standard of reference (including panendoscopy or
bronchoscopy or oesophageal or colon endoscopy when nec-
essary) was 9.5%. Of these, synchronous primaries, 47 (84%)
were detected in 41 patients (93%) by 18F-FDG-PET/CT.
Interestingly, in 32 out of 40 patients (80%) with available
follow-up, the treatment was modiﬁed because of the
detection of a synchronous primary.64 They concluded that
18F-FDG-PET/CT detects a considerable number of synchro-
nous primaries (8.0% prevalence) at the initial staging of
patients with HNSCC.
According to Haerle et al65 synchronous primary tumours were
detected in 4.5% of patients by panendoscopy compared with
6.1% by PET/CT. Indeed 26% of lesions detected on PET/CT
were within the coverage of the panendoscopy.65 18F-FDG-PET/
CT was superior to panendoscopy. The sensitivity, speciﬁcity,
PPV and NPV for panendoscopy were 74%, 99.7%, 93% and
98%, respectively. The sensitivity, speciﬁcity, PPV and NPV for
18F-FDG-PET/CT were 100%, 95.7%, 59% and 100%,
respectively.
According to these results64,65 with a negative 18F-FDG-PET/CT,
the extent of endoscopy can be reduced to the area of the pri-
mary tumour.
In summary, PET/CT is an accurate method detecting second
primaries, with a high NPV.64,65,67–69 Nonetheless, it should be
stressed that due to a low PPV (approximately 60%65) in this
setting, additional diagnostic methods are necessary to exclude
false-positive results (inﬂammation and hyperplasia in the HN
region or intestinal polyps can result in false positives). More-
over, whenever possible PET/CT should be performed before
endoscopy and biopsy to avoid false-positive results.26
POSITRON EMISSION TOMOGRAPHY/CT AND
CLINICAL IMPACT ON TREATMENT DECISIONS
Although PET/CT imaging is effective for the staging of
HNSCC, its impact on patient management is somehow con-
troversial. Indeed, to date, the overall impact of PET/CT on
treatment decisions in HNSCC has been rarely explored com-
pared with the number of studies assessing the impact of PETon
staging. However, there are four prospective trials54–57 that have
speciﬁcally analyzed the impact of PET/PET-CT in the treatment
approach of HNSCC. These studies followed the same meth-
odology and are detailed in Table 4. These studies addressed at
the same time the issue of the impact of PET on the initial
BJR Cacicedo et al
10 of 23 birpublications.org/bjr Br J Radiol;89:20160217
staging and management of patients with HNSCC: globally, the
PET changed the original treatment plan in approximately 30%
of patients.54–57
The largest trial, published by Lonneux et al55 included
233 patients (Stages I–IV) and reported a modiﬁcation in the
original treatment plan in 32 patients (13.7%). In 12 patients
(5.2%), the modiﬁcation was classiﬁed as medium (the thera-
peutic modality remained the same, but PET altered the treat-
ment planning). In 20 patients (8.6%), the impact of PET on
patient management was classiﬁed as high (change in treatment
intent and/or treatment modality, e.g. curative to palliation,
surgery to chemoradiation and so on). Interestingly, one of the
studies57 assessed together the usefulness of PET/CT for staging
and its overall impact on management plans speciﬁcally in
patients with Stages III and IV HNSCC where the treatment plan
was altered in 22/84 (26%) patients (Table 4). These results are
in line with the current guidelines.2,3
In summary, PET/CT should be included54–57 in the routine
diagnosis of patients with Stages III–IV57 HNSCC, as it signiﬁ-
cantly improves staging accuracy and also has a marked impact
on management plans.
RADIOTHERAPY PLANNING
CT is the primary imaging modality in RTP. The CT images are
acquired with the patient in the supine position, immobilized
with an individual head support and a rigid customized mask to
increase positioning accuracy and to prevent movement during
image acquisition. All other imaging modalities (such as PET or
MRI) are considered as secondary images.70 The secondary
images in RTP will have to be registered (fused) to the primary
planning CT scan. When the PET and RTP CT images are ac-
quired on separate scanners (often in a position that does not
correspond to real treatment position), a registration module in
the RTP computer system can be used to fuse images. Regardless
of the imaging data used (i.e. separate PET or PET/CT) correct
co-registration of the PET data with the CT data used for RTP
must be veriﬁed, since the difference in spatial localization of
tumour may lead to false estimation of the gross tumour volume
(GTV). Ideally, the fusion process can be executed automatically
by a hybrid PET-CT-dedicated RTP scanner performed with the
corresponding immobilization devices and reproducing radia-
tion delivery conditions.70
Recognizing the potential of PET/CT-guided treatment plan-
ning, some authors recently investigated the role of PET in RTP,
speciﬁcally for the correct delineation of lymph nodes. Schinagl
et al71 compared the volume of metastatic lymph nodes between
18F-FDG-PET/CT segmentation (by ten methods) and CT with
the volume as determined by pathological examination. They
concluded that beyond the detection of lymph node metastasis
(staging), PET has no additional value over CT for the de-
lineation of lymph nodes.
Despite the limited role of PET-CT in improving the contouring
of nodes,71 it seems to have a main role in improving the def-
inition of the primary tumour GTV. Indeed, PET/CT in-
formation is frequently integrated in RTP. Nevertheless, the use
of 18F-FDG-PET for target volume delineation in RTP for
HNSCC has been mainly evaluated in single institution
studies.5,31,72–75
Different segmentation methods have been proposed. Visual
interpretation of the PET signal, considered the most intuitive
method for segmentation, has been commonly applied in many
studies. The main limit of this approach is that it is a highly
operator-dependent process, and it is inﬂuenced by window-level
settings.5,74–76 This is one of the major weakness in the use of
PET-CT in the target volume delineation of HNSCC. This vari-
ability could be reduced by using a more objective methodology:
isocontouring based on a ﬁxed standardized uptake value (SUV)
such as a SUV of 2.5–3 g l21 or relative thresholds such as a per-
centage of the maximum tumour intensity (40% SUVmax, 50%
SUVmax).
75,77 Nevertheless, according to this method, several
structures containing a high physiological 18F-FDG uptake, such
as the tonsillar area or the vocal cords, can be incorrectly included
in the segmented area. Therefore, models using a ﬁxed threshold
relying on SUV are somehow debatable.73
To overcome this issue, several authors successfully developed
advanced adaptive relative threshold segmentation methods
based on maximal tumour uptake, background uptake, tumour
dimensions and tumour grade.31,75,78,79 Thereafter, other
methods including gradient-based73 detections have been in-
troduced. In brief, this method relies on the watershed trans-
form and hierarchical cluster analysis, to allow a better
estimation of the gradient intensity. Interestingly, this method
allows automatic delineation and therefore is an operator-
independent process. Most studies comparing GTV deﬁnitions
using 18F-FDG-PET against CT or MRI reported a decrease in
the GTV, especially when using more sophisticated segmentation
methods.5,31,72–74,76,80
However, few groups have validated delineation process using
different imaging modalities against surgical resection
specimens.31,81–85 In general, all imaging modalities over-
estimated the tumour extension compared with surgical speci-
men. Nevertheless, none of the image modalities (CT, MRI or
PET) completely encompassed the surgical specimen volume
because of an underestimation of superﬁcial tumour extension
in the mucosa,31 as also reported by Ng et al.81
According to Daisne et al,31 the GTV delineated from 18F-FDG-
PET applying an adaptive signal-to-background method was
signiﬁcantly smaller than GTV delineated by CT or MRI. In
addition, GTV-PET was the closest volume to the pathological
GTV obtained from surgical specimen. On average, the PET
delineated smaller volumes than CT or MRI. Nevertheless, GTV
contours at PET were not totally encompassed by those de-
lineated with CT or MRI.
Geets et al73 validated a gradient-based method in seven patients
with laryngeal carcinoma. The calculated volumes for laryngeal
tumours according to this methodology73 were compared with
the macroscopic specimens and, additionally, with the volumes
obtained applying the source-to-background ratio developed by
Daisne et al.31 Interestingly, the gradient-based method proved
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to be more accurate than the source-to-background ratio but
neither the threshold-based nor the gradient-based volumes
encompassed completely the laryngeal specimens.
Interestingly, in a recent multicentric prospective study by
Leclerc et al,86 the primary tumour was automatically delineated
on the 18F-FDG-PET images using a gradient-based method
previously described by this group.73 They conﬁrmed that the
use of 18F-FDG-PET translated into smaller GTV, clinical target
volume and planning target volume for the primary tumour
volumes compared with the use of CT, lowering the dose to
organs at risk.
On the other hand, there are studies with other tracers such as
ﬂuorine-18 ﬂuorothymidine (18F-FLT) evaluating promising
PET-segmentation methods for delineation of the proliferative
volume (PV) of tumour. In contrast to 18F-FDG, 18F-FLT does
not accumulate in inﬂammatory tissue,87 which is frequently
found in/near primary tumours of the HN or is induced during
the course of chemoradiation. Arends et al88 evaluated
46 patients who underwent 18F-FLT PET/CT prior to treatment
and in the second and fourth week of therapy. The goal of the
study was to compare three semiautomatic PET segmentation
methods for derivation of PV in primary HNSCC on sequential
18F-FLT PET images before and during chemoradiation. The
following semiautomatic segmentation methods were applied to
sequential PET scans: background-subtracted relative-threshold
level, a gradient-based method using the watershed transform
algorithm and hierarchical clustering analysis and a fuzzy locally
adaptive Bayesian algorithm. The authors88 concluded that fuzzy
locally adaptive Bayesian algorithm (FLAB) was the best per-
forming method for segmentation of the PV on repeat 18F-FLT
PET/CT scans during chemoradiation. FLAB is less sensitive to
image noise than the other segmentation approaches tested in
the study. This ﬁnding may have other potential implications for
radiotherapy indicating that FLAB is a promising candidate for
radiation target volume adaptation based on sequential 18F-FLT
PET scanning.
Currently, there is still no consensus (national/international)
between institutions regarding the best method to use for de-
lineation. Therefore, data from 18F-FDG-PET can complement
other diagnostic imaging modalities for management decisions
and guidance of RTP, but it cannot replace physical examination
or MRI/CT scans to achieve signiﬁcant details such as assessing
invasion of tumour-surrounding tissues.85 Moreover, deﬁning
the primary tumour boundaries with PET is a difﬁcult task.
In summary, current evidence is based on numerous heteroge-
neous small studies with changing methodology for different
research questions. PET-based RTP is a promising modality to
improve contouring accuracy. PET is the imaging modality that
deﬁnes the closest volume to the pathological specimen. The
main drawback is the lack of standardized method for functional
volume segmentation, which highly inﬂuences the size and
shape of the resulting GTV. Currently, the most accurate seg-
mentation method seems to be the gradient-based method
validated by Geets et al.73 However, it may not completely en-
compass the tumour specimen volume.31,73 This issue is more
relevant when considering superﬁcial mucosal spread (evaluable
by physical examination).5,81 Therefore, even in some contem-
porary HNSCC study protocols (European Organisation for
Research and Treatment of Cancer-1219; NCT01880359), PET-
based target volume delineation is not allowed. Before PET can
reliably be incorporated into routine high-precision RTP,
operator-independent segmentation tools have to be developed
and validated (international consensus), and also, clinical effect
on outcomes should be reﬂected in clinical studies.
MONITORING RESPONSE TO
CHEMORADIOTHERAPY: RESIDUAL DISEASE AND
RECURRENCE (FOLLOW-UP)
Early detection of residual or recurrent disease following ra-
diotherapy is a diagnostic challenge owing to post-treatment
anatomical distortions, mostly related to oedema and ﬁbrosis.89
The key role of a diagnostic tool evaluating treatment efﬁcacy is
to correctly identify patients requiring salvage-tailored treat-
ments. Moreover, an early detection of the relapse could help in
the selection of patients who could be successfully retreated.90 In
this setting, 18F-FDG-PET/CT is an interesting modality to
evaluate response to treatment, as it can assess metabolic
activity-rendering malignant process.89
Isles et al91 preformed a meta-analysis reporting that 18F-FDG-
PET (without CT) is a highly accurate tool for monitoring re-
sponse and detecting relapse after chemoradiotherapy (for both
the primary site and lymph nodes). Moreover, several studies
have demonstrated that 18F-FDG-PET/CT also has a higher ac-
curacy in the detection of recurrent lesions compared with CT/
MRI.6,92–96 These results obtained with PET/CT are not signif-
icantly different from those obtained with PET alone.
The timing of PET/CT after the treatment is crucial.6,97–101 It is
widely accepted that PET has a high NPV (around 90%) if it is
performed at least 8 weeks after chemoradiotherapy. Therefore,
a negative PET scan after treatment appears to be a consistent
predictor of the absence of residual tumour.102 According to
other reports, more accurate evaluation is possible when PET/CT
is performed 8–12 weeks after treatment.6,97 The meta-analysis
of Gupta et al showed a weighted mean (95% CI)-pooled sensi-
tivity, speciﬁcity, PPV and NPV of post-treatment 18F-FDG-PET
(CT) for the primary site of 79.9% (73.7–85.2%), 87.5%
(85.2–89.5%), 58.6% (52.6–64.5%) and 95.1% (93.5–96.5%),
respectively. Similar estimates for the neck were 72.7%
(66.6–78.2%), 87.6% (85.7–89.3%), 52.1% (46.6–57.6%) and
94.5% (93.1–95.7%), respectively. Moreover, two recent studies
showed even further increased accuracy with delayed PET/CT
performed approximately 4 months after treatment with NPVs
reaching 100%.100,101 Intuitively, delaying a response evaluation
tool would surely increase its accuracy. However, there is no
homogeneous data for optimal window for salvage treatment;
probably, it would be wise not to postpone salvage surgery beyond
a clinically reasonable point.
There is debate regarding the need for elective neck dissection
after radical chemoradiotherapy. There are two prospective
studies98,99 addressing the status of neck adenopathy of node-
positive HNSCC that had 18F-FDG-PET/CT at least 12 weeks
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after chemoradiotherapy. Porceddu et al98 prospectively evalu-
ated 112 patients presenting with radiological nodal complete
response. Residual CT nodal abnormalities were present in
50 patients (45%): 41 were PET negative and 9 were PET pos-
itive. Patients with residual CT nodal abnormalities deemed PET
negative were uniformly observed regardless of residual nodal
size. Importantly, 41 of the 50 patients with a residual nodal
abnormality were spared a neck dissection on the basis of neg-
ative posttherapy PET, with no subsequent nodal failures in this
group. Wang et al99 prospectively evaluated 44 restaging PET/CT
between 12 and 17 weeks after radiotherapy completion, and 10
PET/CT performed in the follow-up of 44 patients. Imaging data
were compared with clinicopathological outcomes. For cervical
lymph nodes, sensitivity was 100%, speciﬁcity was 98%, PPV
was 92% and NPV was 100%. Therefore, both these prospective
studies concluded that PET-guided management of the neck
after chemoradiotherapy appropriately spares neck dissections in
patients with complete response or presenting with PET-
negative residual CT lesions.98,99
Recently, Mehanna et al103 published a prospective, randomized
controlled trial assessing the non-inferiority of PET/CT-guided
surveillance (evaluation was performed 12 weeks after deﬁnitive
chemoradiation. Neck lymph node dissection was only indicated
when PET/CT presented an incomplete or equivocal response)
to planned neck dissection in a total of 564 patients with locally
advanced HNSCC (Stage N2 or N3 disease), who underwent
chemoradiation for primary treatment.
Patients were considered to have incomplete nodal responses
when PET/CT performed 12 weeks after treatment showed high
18F-FDG uptake (with or without enlarged lymph nodes in the
neck). In addition, results of PET/CT presenting mild or no 18F-
FDG uptake in enlarged lymph nodes or mild 18F-FDG uptake
in normal-sized nodes were classiﬁed as equivocal responses.
The rest of the PET/CT scans were classiﬁed as complete
responses. Patients showing an incomplete or equivocal response
in the neck but presenting a complete response in the primary
location underwent neck lymph node dissection within 4 weeks
after PET/CT.
The survival rate was similar (2-year overall survival rate of
84.9% and 81.5% in the surveillance group and in the planned-
neck dissection group, respectively) between patients who
underwent PET/CT-guided surveillance policy and patients
undergoing a planned surgery. Indeed, the hazard ratio for death
(upper boundary of the 95% CI for the hazard ratio, ,1.50; p 5
0.004) favoured PET/CT-guided surveillance policy.
Moreover, surveillance resulted in considerably fewer operations
(approximately 80% of patients were spared neck dissection
compared with planned dissection surgery; 54 vs 221), and it
was more cost effective. The per-person cost saving was £1492
(approximately $2190 in US dollars), with an additional 0.08
quality-adjusted life years per person.
However, these authors recommended that patients with an
equivocal 18F-FDG uptake should continue to undergo neck
dissection. In addition, when extrapolating these results to daily
clinical practice, it should be noted that in this study, only
a small number of patients [17/564 (3%)] presented N3 disease.
Therefore, a direct extrapolation of a PET/CT-guided surveil-
lance policy to patients presenting N3 (Stage IVb) disease should
not be indicated owing to the small number of such patients
recruited in the study.
18F-FDG-PET/CT could have a potential interesting role in the
follow-up of patients with HNSCC. Despite that, the clinical
advantages and economic costs of this issue have not yet been
largely addressed. One of the largest studies has been published by
a group from Pittsburg.90 They evaluated 388 patients retrospec-
tively to assess the recurrence rate after radical chemoradiotherapy
among patients who underwent PET/CT surveillance. Tumour
recurrence was detected in 110 patients (73 asymptomatic and 37
symptomatic). Indeed, 95% (95% CI, 87–98%) of asymptomatic
recurrences were observed within 2 years of follow-up. The authors
proposed to evaluate patients for recurrence with PET/CT at 2, 5, 8
and 14 months post-treatment. The reason for this protocol is
because their study demonstrated that PET/CT detected almost all
HNSCC recurrences within 2 years.
IN SUMMARY
(1) The overall diagnostic performance of 18F-FDG-PET/CT
for response assessment is good, but its PPV is not
optimal. By contrast, the NPV is particularly high and
negative post-treatment PET/CT is very suggestive of
absence of viable disease that can guide daily clinical
management decisions. In this context, the timing of
PET/CT after the end of the treatments is a crucial issue.
Available evidences suggest waiting a minimum of 8 weeks
before restaging with PET/CT, and preferably 12 weeks to
increase the NPV.
(2) Available evidences suggest that this strategy is safe to
avoid neck dissection in patients presenting negative
PET/CT after CRT.98,99,102 The safety of this attitude is
also conﬁrmed by the results of the PET-NECK study,103
where PET/CT-guided active surveillance showed similar
survival outcomes compared with planned neck dissec-
tion, and considerably fewer neck dissections, and it was
more cost effective. However, extrapolation of a PET-CT-
guided surveillance policy to patients with N3 (Stage IVb)
disease cannot currently be justiﬁed.
(3) Evidence-based recommendations to guide the utilization of
PET/CT in the follow-up of patients with HNSCC do not
exist.2,90
PROGNOSTIC VALUE
Treatment outcome of HNSCC cancer remains heterogeneous.
Identiﬁcation of novel pre-treatment factors (other than tumour
stage, lymph node involvement, anatomical subsite or human
papillomavirus status) that potentially predict long-term out-
come is of great interest.
Quantifying the prognostic value of PET is challenging. In
general, the results of prognostic value of SUV remain un-
determined because of the small sample of most of these studies.
Moreover, it should be considered that HNSCC prognosis also
depends on the initial tumour site; data regarding the prognostic
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Table 6. Currently ongoing trials evaluating the role of positron emission tomography (PET)/CT in clinical practice
ClinicalTrials.gov
identifier
Study type Study design Clinical scenario Purpose
NCT01179360 Observational Prospective
Treatment response
assessment
To determine the performance
of 18F-FDG-PET/CT with respect to
detecting residual lymph node
involvement after chemoradiation in
order to omit planned neck
dissections in patients with locally
advanced potentially operable, N2
and N3 HNSCC
NCT02372890 Observational Prospective Staging
To determine the sensitivity and
speciﬁcity of lymph node staging
with high-resolution 18F-FDG-PET/
CT in HNSCC by correlating PET/
CT with histopathology after neck
dissection
NCT02047201 Interventional
Prospective (safety/
efﬁcacy study)
Prognosis
To evaluate the safety and efﬁcacy of
cisplatin plus IMRT based on
18F-FDG-PET/CT after induction
chemotherapy for locally advanced
HNSCC. To evaluate correlation of
OS, PFS and LRC with metabolic
tumour response, anatomical
tumour response, baseline SUV
and HPV
NCT00606294 Interventional
Prospective
(non-randomized)
New tracers
To evaluate low oxygen areas called
hypoxia within tumours in order to
improve the accuracy of hypoxia
imaging for head and neck cancers
through pixel-by-pixel kinetic
analysis of 18F-FMISO tracer of
dynamic PET images
NCT01341535 Interventional Phase II randomized Radiotherapy planning
To compare standard IMRT, using
only pre-treatment planning
18F-FDG-PET/CT scans to adaptive
(dose painting by numbers)
18F-FDG-PET-voxel intensity-based
IMRT using repetitive per-treatment
planning 18F-FDG-PET/CT to
obtain increase in local control
NCT02273778 Interventional Pilot study Radiotherapy planning
To investigate the use of
co-registered 18F-FDG-PET-CT and
MRI for radiotherapy planning in
locally advanced HNSCC
NCT00147472 Interventional
Prospective
(non-randomized)
Residual disease
To determine the ability of PET to
detect residual cancer in neck lymph
nodes of patients following curative
treatment with radiation therapy.
Then, patients undergo neck
dissection surgery (the PET and CT
results are compared with the
presence or absence of tumours in
the neck nodes)
NCT01235052 Interventional Prospective
Treatment response
assessment
Non-invasive assessment of hypoxia
in cancer. Correlation between
a hypoxic volume determined by
18F-FMISO PET-CT and a treatment
response 2 years after radical
treatment
(Continued)
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value of PET/CT depending on different tumour locations is
scarce in the literature.
Two meta-analyses have been conducted to estimate the effect of
SUVon the prognosis of HNSCC. First, Zhang et al104 analyzed the
potential of SUV [SUVmax and mean SUV (SUVmean)] as a prog-
nostic marker. These authors concluded that increased SUVmax/
mean of the primary tumour is a poor prognosis factor and has
a potential value in predicting local control, disease-free survival
and overall survival. Thereafter, Xie et al105 performed another
meta-analysis to evaluate the prognostic value of SUV, conﬁrming
that low primary tumour SUV was associated with better survival
prognosis. It should be stressed that SUV estimates suffer from
poor reproducibility between centres because of the lack of stan-
dardization of the acquisition and processing protocols.
Globally, studies evaluating the prognostic utility of PET/CT in
HN cancer are quite heterogeneous. Most of them have focused
mainly on the SUVmax. Some studies have demonstrated worse
clinical outcomes with higher pre-treatment SUVmax.
106–108
Other studies observed the correlation of survival with several
PET data such as SUVmean or metabolic tumour volume
(MTV).109,110 Kitajima et al reported111 that the pre-treatment
SUVmax of nodal disease (rather than the primary tumour) in
patients with laryngeal cancer was prognostic of recurrence.
However, a prospective trial7 conducted at the MD Anderson
Cancer Center, Houston, TX, evaluated this particular question
and failed to demonstrate any signiﬁcant clinical correlation
between pre-radiotherapy PET-CT SUV parameters and treat-
ment outcomes.
According to other authors, SUVmean
109,112 may be a better
prognosis marker than SUVmax, with inferior disease-free
survival in patients presenting higher pre-treatment SUV-
mean.
109 These results could be explained considering that
SUVmax reﬂects the highest intensity of
18F-FDG uptake as
measured in the highest pixels within a concrete region of
interest, whereas the SUVmean represents the average of the
intensity of the uptake providing a more global picture of
tumour metabolism than SUVmax.
109 Nevertheless, a potential
pitfall of SUVmean is the lesser degree of reproducibility rel-
ative to SUVmax.
109
More recently, there has been an increasing interest in the use of
volumetric parameters of metabolism such as the MTV and total
lesion glycolysis (TLG), which weights the volumetric burden and
volumetric activity of tumours. Pak et al113 conducted a meta-
analysis (13 studies including 1180 patients) on volumetric
parameters addressing the prognostic value of MTV and TLG in
patients with HN cancer. Despite the various methods adopted
between studies, these authors concluded that MTV and TLG are
accurate prognostic indicators of outcome in patients with HN
cancer. Indeed, high MTV and TLG increased the risk of disease
progression and death. The studies evaluated in the meta-analysis
and more recent contemporary studies110,112,114–129 are described
in Table 5.
Table 6. (Continued)
ClinicalTrials.gov
identifier
Study type Study design Clinical scenario Purpose
NCT02262221 Interventional Randomized (Phase II) Follow-up
To evaluate the cost effectiveness of
two different follow-up programs in
head and neck cancer survivors.
ARM A (non-intensive follow-up)
and ARM B (intervention foreseen
is scheduled radiologic evaluations:
CT or MRI scan and PET scan if
patients $50 years old and with
a smoking history of $20 packs
per year)
NCT00954148 Interventional Randomized Follow-up
To show that PET/CT will be
superior (15% improvement) to
conventional methods of follow-up
in terms of 5-year survival, cost
and time to identiﬁcation of
new disease
NCT00159978 Observational Prospective (Phase I) New tracers
To validate 18F-FMISO-PET for
detection of tumour hypoxia and
18F-FLT-PET for detection of
tumour cell proliferation by
immunohistochemical assessment of
hypoxia and proliferation in head
and neck cancer resection specimen
18F-FDG-PET/CT, PET with fluorine-18 fludeoxyglucose integrated with CT; 18F-FLT, fluorine-18 fluorothymidine; 18F-FMISO, fluorine-18 fluoromiso-
nidazole; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; IMRT, intensity-modulated radiotherapy; LRC, locoregional
control; OS, overall survival; PFS, progression-free survival; SUV, standardized uptake value.
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In summary, meta-analysis and several studies showed that PET-
quantiﬁed data such as SUVmax, SUVmean, MTV, TLG are
strongly and negatively correlated with survival. However, given
that some uncertainty still exists on which of these parameters
are the best predictors, prospective trials are needed to de-
ﬁnitively settle this issue.
POSITRON EMISSION TOMOGRAPHY/MRI:
ADDING NEW POSSIBILITIES
Since information provided by PET/CT and MRI is comple-
mentary in many clinical situations, it seems to make sense to
combine the two modalities. The high soft-tissue contrast and
the different functional imaging techniques of MRI might help
to ameliorate the informative value of a hybrid imaging study.
Consequently, the discussion about potential applications of this
new hybrid technology in oncological imaging and especially in
the HN has been generated.130
The feasibility131 and diagnostic performance (sensitivity, spec-
iﬁcity and accuracy) of clinical PET/MRI have been demon-
strated in a signiﬁcant number of studies,51,85 but technological
and logistic challenges, such as errors in attenuation correction
and long scan duration continue to be a major focus of the PET/
MRI literature.132
PET/MRI has many potential advantages over PET/CT (including
perineural spread of tumours and the inﬁltration of important
anatomical landmarks, such as the pre-vertebral fascia and great
vessel walls; lower radiation exposure, higher soft-tissue contrast
and several functional techniques).133 Realizing this potential in
clinics will likely require new radiopharmaceuticals and applica-
tions other than WB cancer staging.132
Although PET/MRI is still in the early stages of clinical de-
velopment, it is clear that the clinical adoption of PET/MRI is
slower than that of PET/CT. This slower evolution is not only
due partly to ongoing technological challenges (e.g. accurate
attenuation correction of PET images) but also to the complex
logistics of combining a WB PET scan with WB or organ-speciﬁc
MRI. Key applications of PET/MRI that provide information
that is clinically relevant and different from that provided by
PET/CT still need to be deﬁned.134
Further studies that exploit the functional MRI and molecular
PET capabilities may report substantial contributions of PET/
MRI for treatment response predictions, radiotherapy planning,
tumour phenotyping and treatment monitoring.131,135,136
Future research involving larger patient series is needed to assess
the true impact of this technique in HNSCC and will show
whether PET/MRI outperforms PET/CT, MRI, diffusion-
weighted MRI or their combination.
FUTURE APPLICATIONS OF POSITRON EMISSION
TOMOGRAPHY/CT IN RADIATION ONCOLOGY
Table 6 summarizes some of the ongoing clinical trials (www.
ClinicalTrials.gov) dealing with the issue of PET/CT in HNSCC
treated with radiotherapy.
Table 7. Summary: recommendations and key issues
1.
Unknown primary: 18F-FDG-PET/CT is recommended
to identify primary tumours in patients presenting with
cervical lymph node metastases with unknown primary
2.
Pre-treatment staging: Multiple studies have
demonstrated that adding PET (or PET/CT) to
a conventional work-up resulted in a higher staging
accuracy; nodal classiﬁcation is improved, especially in
terms of speciﬁcity; and 18F-FDG-PET or PET/CT
detects more distant metastases and second malignancy
than conventional staging
3.
Clinical impact: A more reﬁned staging has
demonstrated to have clinical impact on treatment
decisions. PET/CT should be included in the routine
diagnosis of patients with Stages III–IV HNSCC, as it
signiﬁcantly improves staging accuracy and also has
a marked impact on management plans. However, there
is no evidence with regard to a possible beneﬁt in
outcomes due to PET/CT
4.
Radiotherapy: The use of 18F-FDG-PET translates into
smaller GTV for the primary tumour volumes than with
the use of CT or MRI. PET can complement other
diagnostic imaging modalities for management decisions
and guidance of radiotherapy planning, but it cannot
replace physical examination or MRI/CT. There is no
current standardized method for functional volume
segmentation recommended for daily practice
5.
Monitoring response to treatment: PET/CT is
recommended to check for residual disease at least 8
and, preferably, 12–16 weeks after deﬁnitive
chemoradiotherapy in node-positive HNSCC (NPV
.90%), avoiding unnecessary neck dissections in
patients presenting complete response. Mehanna
et al103 indicated that patients with incomplete
(presenting high 18F-FDG uptake at 12 weeks after
chemoradiotherapy, with or without enlarged lymph
nodes in the neck), or equivocal response (mild or no
18F-FDG uptake in enlarged nodes or mild 18F-FDG
uptake in normal-sized nodes) should undergo neck
dissection. Few patients in this trial had N3 (Stage IVb)
disease [17/564 (3%)]. Therefore, a PET-CT-guided
surveillance policy to patients presenting N3 disease is
not currently justiﬁed due to the small number of
patients presenting N3 disease in this study
6.
Surveillance: PET/CT is not indicated in routine
follow-up
7.
Prognosis: Patients presenting increased SUV (SUVmax,
SUVmean) or higher MTV or TLG seem to have worse
prognosis (higher risk of treatment failure). There is no
currently evidence to support that this type of patients
should receive different treatment approach.
Nevertheless, these parameters could be used to stratify
patients in future clinical trials
8.
To further validate incorporating PET/CT into daily
practice also, clinical effect on outcomes and
cost effectiveness should be reﬂected in clinical
studies
18F-FDG, fluorine-18 fludeoxyglucose; GTV, gross tumour volume;
HNSCC, head and neck squamous cell carcinoma; MTV, metabolic
tumour volume; NPV, negative-predictive value; PET, positron emission
tomography; SUV, standardized uptake value; SUVmax, maximal SUV;
SUVmean, mean SUV; TLG, total lesion glycolysis.
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Dose escalation to 18F-FDG-avid subvolumes of the tumour as
well as adapting the RTP during treatment regarding the func-
tional tumour changes induced during radiation are two im-
portant issues that are currently under investigation.137–139
Madani et al140 performed a Phase I trial to establish the
maximum tolerated dose, when the dose was escalated in
18F-FDG-PET GTV within the anatomically (CT/MRI) based
GTV. They demonstrated the feasibility of heterogeneous dose
delivery with dose escalation up to 77.5 Gy for 18F-FDG-avid
tumour areas (the so called “dose painting” approach).
Another approach would be adaptation of the biological target
volume during the course of radiotherapy in order to reduce
Figure 1. Proposal to incorporate positron emission tomography (PET)/CT (contrast-enhanced CT) into routine clinical practice for head
and neck squamous cell carcinoma. †Cervical metastases from unknown primary cancer (UPC). *Evaluate to include MRI to assess soft-
tissue invasion or perineural spread if needed depending on primary tumour location.16 VPrognosis: uptake parameters and volumetric
parameters can potentially help in identifying patients with worse outcomes (still an area of active investigation). ¥Radiotherapy (RT)
plan: PET/CT may be helpful, improving contouring accuracy. However, standardized method is lacking. pFollow-up with conventional
imaging (CT/MRI) is recommended. When equivocal findings additional PET/CT can be performed. mOnce recurrence is detected,
additional PET/CT may be of interest to improve patient counselling; restaging the tumour and planning additional therapy, especially
when “aggressive” interventions (extended surgery or reirradiation) may be needed. SHowever, Mehanna et al103 indicated that patients
with incomplete [patients presenting high fluorine-18 fludeoxyglucose (18F-FDG) uptake at 12 weeks after chemoradiotherapy, with or
without enlarged lymph nodes in the neck] or equivocal response (mild or no 18F-FDG uptake in enlarged nodes or mild 18F-FDG uptake in
normal-sized nodes) should undergo neck dissection. In addition, it should be noted that few patients in this trial had N3 (Stage IVb)
disease [17/564 (3%)]. Therefore, a PET-CT-guided surveillance policy to patients presenting N3 disease is not justified due to the small
number of patients presenting N3 disease in this study. CR, complete response; QT, chemotherapy.
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the treated volume as radiotherapy progresses. Duprez et al138
used adaptive intensity-modulated radiotherapy planning based
on dose painting by numbers according to 18F-FDG-PET voxel
intensities concluding that replanning was possible reaching a to-
tal dose of 80.9Gy. It is noteworthy that these kinds of approaches
require extreme attention, as a slight shift of the anatomy will not
only cause a mismatch of dose and intratumour anatomy but also
a higher dose into nearby healthy tissue. Moreover, another un-
solved issue is the monitoring of the shift of high SUV regions
during the course of treatment.
Last but not least, the possibility of targeting radiation resistance
within the tumour on the basis of biological information
(intratumoural hypoxic and proliferation states) obtained from
functional imaging with other tracers than 18F-FDG is an
emergent strategy.141–143 However, this issue is still under in-
vestigation and should still be considered as experimental.144,145
CONCLUSION
PET/CT is an important diagnostic tool in HN oncology,
especially in the initial staging and in monitoring response to
deﬁnitive chemoradiotherapy. Moreover, approaches of neck
dissection sparing based on the results of restaging PET/CT are
safe and should be implemented in daily clinical practice. The
summary of indications and controversies are detailed in
Table 7. Based on the results of our review, we summarized in
Figure 1 a proposal for integrating PET/CT in daily clinical
practice.
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